1. Scrip
  2. >>R&D

Crisis Deepens At IGM Biosciences As Autoimmune Gambit Fails

 
• By Andrew McConaghie

The company’s IgG antibody constructs have now failed in oncology and autoimmune disease, leaving it with few remaining strategic options.

(Shutterstock)

In September, IGM Biosciences decided to pivot into autoimmune diseases after failure in oncology, but the strategy has already foundered. The company has halted development of its two lead candidates, plunging it deeper into crisis and leaving it with no clear strategic plan other than to slash nearly three quarters of its workforce to cut costs.

IGM announced on 9 January that it was discontinuing its lead asset, imvotamab, an IgM-based CD20xCD3 bispecific antibody T-cell engager after disappointing interim Phase Ib results in rheumatoid arthritis and...

Key Takeaways
  • IGM Biosciences pivoted to its two back-up autoimmune candidates in September - but has now abandoned these as well.
  • The move leaves...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from Business

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.